Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer

Table 5 Levels of CD44V6 and tumor supplied group of factor in each group (mean ± SD)

Group	CD44V6 (ng/mL)		TSGF (ng/mL)
	Before treatment	After treatment	Before treatment	After treatment
Control (n = 50)	512.45 ± 33.06	367.56 ± 24.67	74.35 ± 6.57	56.87 ± 5.76
Observation (n = 75)	513.52 ± 34.11	314.23 ± 20.12	72.78 ± 6.54	42.38 ± 5.21
t	0.174	12.719	1.312	14.600
P value	0.862	< 0.001	0.192	< 0.001

TSGF: Tumor supplied group of factor.